Call for Abstracts

The on-line abstracts submission procedure has been completed.

Please note that your abstract’s corresponding author will be notified of the evaluation procedure’s results until April 22, 2019.
For further information regarding abstract submission and presentation, please contact the Conference Organizing Secretariat at

Submission procedure & guidelines

Please read the below information  before entering the online abstract submission system:

Meeting topics
  1. Basic research/Translational research
  2. Pathology
  3. Diagnostic imaging
  4. Surgical margin/CTx evaluation
  5. Clinical Trial/Chemotherapy/Immunotherapy
  6. Molecular-targeted therapy
  7. Radiotherapy/IVR
  8. Functional results and quality of life
  9. Navigation and robotics
  10. Joint-sparing surgery
  11. Recycled bone graft/Local tumor ablation
  12. Allograft/Vascularized bone graft
  13. Prosthetic reconstruction
  14. Limb salvage in children
  15. Soft-tissue reconstruction
  16. Complications in tumor surgery
  17. Spinal and sacral tumors
  18. Pelvic tumors
  19. Metastasis
  20. Innovative treatments
  21. Benign tumors
  22. Soft-tissue sarcomas
  23. Bone sarcomas
  24. Disasters in limb salvage
  25. Cancer and pain
  26. Amputation and rehabilitation
  27. Other

Abstract Regulations
  • Abstracts can only be submitted electronically through the ISOLS 2019 website.
  • Acknowledgement of receipt of your submission will be sent to your stated email address. If you do not receive the confirmation email within 24 hours, please contact us at
  • Abstracts must be written in English.
  • Maximum 400 words, excluding title and authors list and affiliations.
  • It is the author's responsibility to submit a complete abstract in finalized format. Any errors in spelling, grammar or scientific facts will be reproduced as typed by the author.
  • The presenting author is indicated by clicking on the appropriate box next to the respective name. The same author can present a maximum of three (3) abstracts. Co-authorship is open to an unlimited number of abstracts.
  • Submission of closely related abstracts from the same group is discouraged.
  • Abstracts will only be considered for presentation if they are not published or submitted for presentation elsewhere.
  • Abstract presenters must be registered for ISOLS 2019 and have paid their registration fee in full until May 5, 2019.

Notification of Acceptance
  • Notification of acceptance or rejection of the abstract will be sent to the corresponding author of each abstract by April 22, 2019.
  • Accepted abstracts will be considered for oral, poster discussion or poster presentations.
  • The corresponding author receives all information concerning the abstract and is responsible for informing all other co-authors of the status of the abstract.
  • All abstract presenters will be asked to reconfirm their attendance after receiving the notification. If you do not reconfirm your abstract presentation, register and pay the registration fee before the given deadline, your abstract will be removed from the program.

Presentation of Abstracts
Accepted abstracts will be presented in Platform, Flash and Poster sessions.

Abstract Submission Terms and Conditions
  1. Authors can modify the author information, category and core data of their abstract directly on the submission system until the deadline given. Please be aware that no extension will be granted.
  2. By submitting an abstract, submitters understand that their abstract, including names, is stored electronically and will be published by the Organizing Committee on the ISOLS 2019 website. Failure to present the abstract on-site will result in exclusion from online publishing.
  3. No trade names of products are allowed in oral or poster presentations. Non-proprietary (generic, chemical) names of drugs should be used. Company names can be used in the authors affiliation and as a source to a material mentioned in the body of the abstract, such as "Imiquimod (3M, Milwaukee, USA) was used to stimulated dendric cells".
  4. Abstracts will be assessed by an expert panel of reviewers. Acceptance of the submitted work is at the discretion of the Scientific Committee.
  5. The corresponding author receives all correspondence concerning the abstract and is responsible for informing all co-authors of the status of the abstract.
    The presenting author of an abstract must register for the Meeting by the given deadline. If registration and payment is not completed within the deadline, the abstract will be removed from the program.
  6. Consent for publication of individual patient data (applies to abstracts with identifiable patient information): For publication of an abstract that contains identifiable information about patients, it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent must be obtained from the patient (or their parent or legal guardian) and a respective statement should be included in the abstract text.
  7. Duplication of publication
    ISOLS does not accept re-submission; abstracts must correspond to original, previously unpublished work. By submitting an abstract, the submitter confirms that he/she has not presented/plans to present and publish the abstract at another meeting, and that he/she has not submitted/published the full paper.
  8. Declaration of Conflict of Interest: ISOLS is committed to ensuring the integrity of its scientific, educational, and research programs. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.

For abstract submission support please contact the ISOLS 2019 Meeting Secretariat at